Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Hepatocellular Carcinoma Treatment Market Segmentation
Frequently Asked Questions
2023 is the base year and 2030 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1.Executive Summary
2.Global Hepatocellular Carcinoma Treatment Market Introduction
2.1.Global Hepatocellular Carcinoma Treatment Market - Taxonomy
2.2.Global Hepatocellular Carcinoma Treatment Market - Definitions
2.2.1.Route of Administration
2.2.2.Drug
2.2.3.Distribution Channel
2.2.4.Region
3.Global Hepatocellular Carcinoma Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Hepatocellular Carcinoma Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Hepatocellular Carcinoma Treatment Market By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Oral
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Injectable
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6.Global Hepatocellular Carcinoma Treatment Market By Drug, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Atezolizumab
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Avelumab
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Bevacizumab
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Durvalumab
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Erlotinib
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Gefitinib
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Regorafenib
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Sorafenib
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Tremelimumab
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Cabozatinib
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
6.11. Ramucirumab
6.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.11.3. Market Opportunity Analysis
6.12. Others
6.12.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.12.3. Market Opportunity Analysis
7.Global Hepatocellular Carcinoma Treatment Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacy
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacy
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacy
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8.Global Hepatocellular Carcinoma Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9.North America Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Oral
9.1.2.Injectable
9.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Atezolizumab
9.2.2.Avelumab
9.2.3.Bevacizumab
9.2.4.Durvalumab
9.2.5.Erlotinib
9.2.6.Gefitinib
9.2.7.Regorafenib
9.2.8.Sorafenib
9.2.9.Tremelimumab
9.2.10.Cabozatinib
9.2.11.Ramucirumab
9.2.12.Others
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Hospital Pharmacy
9.3.2.Retail Pharmacy
9.3.3.Online Pharmacy
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Oral
10.1.2.Injectable
10.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Atezolizumab
10.2.2.Avelumab
10.2.3.Bevacizumab
10.2.4.Durvalumab
10.2.5.Erlotinib
10.2.6.Gefitinib
10.2.7.Regorafenib
10.2.8.Sorafenib
10.2.9.Tremelimumab
10.2.10.Cabozatinib
10.2.11.Ramucirumab
10.2.12.Others
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.Hospital Pharmacy
10.3.2.Retail Pharmacy
10.3.3.Online Pharmacy
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Oral
11.1.2.Injectable
11.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Atezolizumab
11.2.2.Avelumab
11.2.3.Bevacizumab
11.2.4.Durvalumab
11.2.5.Erlotinib
11.2.6.Gefitinib
11.2.7.Regorafenib
11.2.8.Sorafenib
11.2.9.Tremelimumab
11.2.10.Cabozatinib
11.2.11.Ramucirumab
11.2.12.Others
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Hospital Pharmacy
11.3.2.Retail Pharmacy
11.3.3.Online Pharmacy
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Latin America Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Oral
12.1.2.Injectable
12.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Atezolizumab
12.2.2.Avelumab
12.2.3.Bevacizumab
12.2.4.Durvalumab
12.2.5.Erlotinib
12.2.6.Gefitinib
12.2.7.Regorafenib
12.2.8.Sorafenib
12.2.9.Tremelimumab
12.2.10.Cabozatinib
12.2.11.Ramucirumab
12.2.12.Others
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.Hospital Pharmacy
12.3.2.Retail Pharmacy
12.3.3.Online Pharmacy
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1.Brazil
12.4.2.Mexico
12.4.3.Rest of LA
13.Middle East and Africa Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1.Oral
13.1.2.Injectable
13.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1.Atezolizumab
13.2.2.Avelumab
13.2.3.Bevacizumab
13.2.4.Durvalumab
13.2.5.Erlotinib
13.2.6.Gefitinib
13.2.7.Regorafenib
13.2.8.Sorafenib
13.2.9.Tremelimumab
13.2.10.Cabozatinib
13.2.11.Ramucirumab
13.2.12.Others
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1.Hospital Pharmacy
13.3.2.Retail Pharmacy
13.3.3.Online Pharmacy
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1.GCC Countries
13.4.2.South Africa
13.4.3.Rest of MEA
14. Competition Landscape
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
14.2.1.AstraZeneca
14.2.2.Bayer AG
14.2.3.Bristol-Myers-Squibb Company
14.2.4.Celgene Corporation
14.2.5.Eisai Co. Ltd
14.2.6.Hoffmann-La Roche Ltd
14.2.7.Merck & Co. Inc.
14.2.8.Pfizer Inc.
14.2.9.Chugai Pharmaceutical Co. Ltd
14.2.10.Pharmaxis
14.2.11.Eli Lilly
14.2.12.BeiGene
15. Research Methodology
16. Appendix and Abbreviations
2.Global Hepatocellular Carcinoma Treatment Market Introduction
2.1.Global Hepatocellular Carcinoma Treatment Market - Taxonomy
2.2.Global Hepatocellular Carcinoma Treatment Market - Definitions
2.2.1.Route of Administration
2.2.2.Drug
2.2.3.Distribution Channel
2.2.4.Region
3.Global Hepatocellular Carcinoma Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Hepatocellular Carcinoma Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Hepatocellular Carcinoma Treatment Market By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Oral
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Injectable
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6.Global Hepatocellular Carcinoma Treatment Market By Drug, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Atezolizumab
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Avelumab
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Bevacizumab
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Durvalumab
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Erlotinib
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Gefitinib
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Regorafenib
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Sorafenib
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Tremelimumab
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Cabozatinib
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
6.11. Ramucirumab
6.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.11.3. Market Opportunity Analysis
6.12. Others
6.12.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.12.3. Market Opportunity Analysis
7.Global Hepatocellular Carcinoma Treatment Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacy
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacy
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacy
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8.Global Hepatocellular Carcinoma Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9.North America Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Oral
9.1.2.Injectable
9.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Atezolizumab
9.2.2.Avelumab
9.2.3.Bevacizumab
9.2.4.Durvalumab
9.2.5.Erlotinib
9.2.6.Gefitinib
9.2.7.Regorafenib
9.2.8.Sorafenib
9.2.9.Tremelimumab
9.2.10.Cabozatinib
9.2.11.Ramucirumab
9.2.12.Others
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Hospital Pharmacy
9.3.2.Retail Pharmacy
9.3.3.Online Pharmacy
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Oral
10.1.2.Injectable
10.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Atezolizumab
10.2.2.Avelumab
10.2.3.Bevacizumab
10.2.4.Durvalumab
10.2.5.Erlotinib
10.2.6.Gefitinib
10.2.7.Regorafenib
10.2.8.Sorafenib
10.2.9.Tremelimumab
10.2.10.Cabozatinib
10.2.11.Ramucirumab
10.2.12.Others
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.Hospital Pharmacy
10.3.2.Retail Pharmacy
10.3.3.Online Pharmacy
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Oral
11.1.2.Injectable
11.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Atezolizumab
11.2.2.Avelumab
11.2.3.Bevacizumab
11.2.4.Durvalumab
11.2.5.Erlotinib
11.2.6.Gefitinib
11.2.7.Regorafenib
11.2.8.Sorafenib
11.2.9.Tremelimumab
11.2.10.Cabozatinib
11.2.11.Ramucirumab
11.2.12.Others
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Hospital Pharmacy
11.3.2.Retail Pharmacy
11.3.3.Online Pharmacy
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Latin America Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Oral
12.1.2.Injectable
12.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Atezolizumab
12.2.2.Avelumab
12.2.3.Bevacizumab
12.2.4.Durvalumab
12.2.5.Erlotinib
12.2.6.Gefitinib
12.2.7.Regorafenib
12.2.8.Sorafenib
12.2.9.Tremelimumab
12.2.10.Cabozatinib
12.2.11.Ramucirumab
12.2.12.Others
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.Hospital Pharmacy
12.3.2.Retail Pharmacy
12.3.3.Online Pharmacy
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1.Brazil
12.4.2.Mexico
12.4.3.Rest of LA
13.Middle East and Africa Hepatocellular Carcinoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1.Oral
13.1.2.Injectable
13.2. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1.Atezolizumab
13.2.2.Avelumab
13.2.3.Bevacizumab
13.2.4.Durvalumab
13.2.5.Erlotinib
13.2.6.Gefitinib
13.2.7.Regorafenib
13.2.8.Sorafenib
13.2.9.Tremelimumab
13.2.10.Cabozatinib
13.2.11.Ramucirumab
13.2.12.Others
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1.Hospital Pharmacy
13.3.2.Retail Pharmacy
13.3.3.Online Pharmacy
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1.GCC Countries
13.4.2.South Africa
13.4.3.Rest of MEA
14. Competition Landscape
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
14.2.1.AstraZeneca
14.2.2.Bayer AG
14.2.3.Bristol-Myers-Squibb Company
14.2.4.Celgene Corporation
14.2.5.Eisai Co. Ltd
14.2.6.Hoffmann-La Roche Ltd
14.2.7.Merck & Co. Inc.
14.2.8.Pfizer Inc.
14.2.9.Chugai Pharmaceutical Co. Ltd
14.2.10.Pharmaxis
14.2.11.Eli Lilly
14.2.12.BeiGene
15. Research Methodology
16. Appendix and Abbreviations
AstraZeneca
Bayer AG
Bristol-Myers-Squibb Company
Celgene Corporation
Eisai Co. Ltd
Hoffmann-La Roche Ltd
Merck & Co. Inc.
Pfizer Inc.
Chugai Pharmaceutical Co. Ltd
Pharmaxis
Eli Lilly
BeiGene
Bayer AG
Bristol-Myers-Squibb Company
Celgene Corporation
Eisai Co. Ltd
Hoffmann-La Roche Ltd
Merck & Co. Inc.
Pfizer Inc.
Chugai Pharmaceutical Co. Ltd
Pharmaxis
Eli Lilly
BeiGene